Thiruvanantha Puram Today

Acute Kidney Injury Market, Size, Share, Trends, Epidemiology Forecast till 2030

 Breaking News
  • No posts were found

Acute Kidney Injury Market, Size, Share, Trends, Epidemiology Forecast till 2030

August 10
16:05 2020
Acute Kidney Injury Market, Size, Share, Trends, Epidemiology Forecast till 2030

DelveInsight Buisness Research LLP
DelveInsight’s “Acute Kidney Injury Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Acute Kidney Injury (AKI), historical and forecasted epidemiology as well as the Acute Kidney Injury (AKI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Acute Kidney Injury is a condition characterized by minor or complete loss of kidney function due to a sudden injury to kidneys.

The Acute Kidney Injury (AKI) market report by DelveInsight provides current treatment practices, emerging drugs, Acute Kidney Injury (AKI) market share of the individual therapies, current and forecasted Acute Kidney Injury (AKI) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Acute Kidney Injury (AKI) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Acute Kidney Injury Epidemiology 

  • The highest incident cases of AKI were recorded in the United States in 2017 was 895,078
  • Among the EU5 countries, Germany had the highest AKI diagnosed cases in 2017 was 82,902
  • Acute Kidney Injury affects males and females equally

Acute Kidney Injury Market 

Market Size of Acute Kidney Injury in the United States in 2017 was USD 2,907 Million 

Acute Kidney Injury Market Drivers

  • Robust Pipeline Activity
  • Increased incidence of hospitalization
  • Reimbursement policies

Acute Kidney Injury Market Barriers

  • Disease burden
  • Morbidity/ mortality
  • Disease management & treatment

Acute Kidney Injury Emerging Therapies

(Drug: companies logos)

  • EA-230: Exponential Biotherapies
  • bRESCAP: Alloksys
  • ANG-3777 : Angion Biomedica
  • QPI-1002: Quark Pharmaceuticals
  • recAP: AM Pharma
  • Reltecimod: AtoxBio
  • ASP1128: Astellas Pharma
  • Levosimendan : Orion Pharma
  • MB-102: MediBeacon
  • Ruconest: Pharming Technologies

Request for sample pages

Table of contents

1. Key Insights

2. The Report contains

3. Acute Kidney Injury Market (AKI): Overview at a Glance

3.1. Market Share Distribution of AKI in 2017

3.2. Market Share Distribution of AKI in 2030

4. Acute Kidney Injury (AKI): Disease Background and Overview

4.1. Introduction

4.2. Symptoms

4.3. Types of Acute Kidney Injury

4.4. Stages Classification

4.5. Risk Factors

4.6. Etiology

4.7. Pathophysiology

4.8. Biomarkers

4.9. Diagnosis

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. 7MM Total Incident Patient Population of AKI

5.3. 7MM Total Discharge Diagnosed Population of AKI

6. United States

6.1. Assumptions and Rationale

6.2. Acute Kidney Injury Incident Cases in the US

6.3. Acute Kidney Injury Discharge Diagnosed Cases in the US

6.4. Acute Kidney Injury Stage-Wise Discharged Diagnosed Cases in the US

6.5. Acute Kidney Injury Risk Factor Associated Cases in the US

6.6. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in the US

7. EU5

7.1. Assumptions and Rationale

7.2. Germany

7.2.1. Acute Kidney Injury Incident Cases in Germany

7.2.2. Acute Kidney Injury Discharge Diagnosed Cases in Germany

7.2.3. Acute Kidney Injury Stage-Wise Discharged Diagnosed Cases in Germany

7.2.4. Acute Kidney Injury Risk Factor Associated Cases in Germany

7.2.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Germany

7.3. France

7.3.1. Acute Kidney Injury Incident Cases in France

7.3.2. Acute Kidney Injury Discharge Diagnosed Cases in France

7.3.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in France

7.3.4. Acute Kidney Injury Risk Factor Associated Cases in France

7.3.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in France

7.4. Italy

7.4.1. Acute Kidney Injury Incident Cases in Italy

7.4.2. Acute Kidney Injury Discharge Diagnosed Cases in Italy

7.4.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in Italy

7.4.4. Acute Kidney Injury Risk Factor Associated Cases in Italy

7.4.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Italy

7.5. Spain

7.5.1. Acute Kidney Injury Incident Cases in Spain

7.5.2. Acute Kidney Injury Discharge Diagnosed Cases in Spain

7.5.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in Spain

7.5.4. Acute Kidney Injury Risk Factor Associated Cases in Spain

7.5.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Spain

7.6. United Kingdom

7.6.1. Acute Kidney Injury Incident Cases in the UK

7.6.2. Acute Kidney Injury Discharge Diagnosed Incident Cases in the UK

7.6.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in the UK

7.6.4. Acute Kidney Injury Risk Factor Associated Cases in the UK

7.6.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in the UK

8. Japan

8.1.1. Assumptions and Rationale

8.1.2. Acute Kidney Injury Incident Cases in Japan

8.1.3. Acute Kidney Injury Discharge Diagnosed Cases Japan

8.1.4. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in Japan

8.1.5. Acute Kidney Injury Risk Factor Associated Cases in Japan

8.1.6. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Japan

9. Treatment and Prevention

10. Unmet Needs

11. Emerging Therapies

11.1. Key cross competition- Emerging Therapies

12. Emerging Therapies

12.1. EA-230: Exponential Biotherapies

12.1.1. Clinical Development

12.1.2. Clinical Trials Information

12.1.3. Safety and Efficacy

12.1.4. Product Profile

12.2. bRESCAP: Alloksys

12.2.1. Other Developmental Activities

12.2.2. Clinical Trials Information

12.2.3. Safety and Efficacy

12.2.4. Product Profile

12.3. ANG-3777 (BB3) : Angion Biomedica

12.3.1. Other Developmental Activities

12.3.2. Clinical Trials Information

12.3.3. Safety and Efficacy

12.3.4. Product Profile

12.4. QPI-1002: Quark Pharmaceuticals

12.4.1. Other Developmental Activities

12.4.2. Clinical Development

12.4.3. Clinical Trial Information

12.4.4. Safety and Efficacy

12.4.5. Advantages and Disadvantages

12.4.6. Product Profile

12.5. recAP: AM Pharma

12.5.1. Other Developmental Activities

12.5.2. Clinical Development

12.5.3. Clinical Trial Information

12.5.4. Safety and Efficacy

12.5.5. Product Profile

12.6. Reltecimod: AtoxBio

12.6.1. Other Developmental Activities

12.6.2. Clinical Development

12.6.3. Clinical Trial Information

12.6.4. Safety and Efficacy

12.6.5. Product Profile

12.7. ASP1128: Astellas Pharma

12.7.1. Other Developmental Activities

12.7.2. Clinical Development

12.7.3. Clinical Trial Information

12.7.4. Safety and Efficacy

12.7.5. Product Profile

12.8. Ruconest (Conestat alfa): Pharming Technologies

12.8.1. Other Developmental Activities

12.8.2. Clinical Development

12.8.3. Clinical Trial Information

12.8.4. Safety and Efficacy

12.8.5. Product Profile

12.9. MB-102: MediBeacon

12.9.1. Other Developmental Activities

12.9.2. Clinical Development

12.9.3. Clinical Trial Information

12.9.4. Safety and Efficacy

12.9.5. Product Profile

12.10. Levosimendan (Simdax): Orion Pharma

12.10.1. Clinical Development

12.10.2. Clinical Trial Information

12.10.3. Safety and Efficacy

12.10.4. Product Profile

13. Acute Kidney Injury: 7 Major Market Analysis

13.1. Key Findings

13.2. Market Size of AKI in 7MM

14. United States Market Outlook

14.1. United States Market Size

14.1.1. Total Market size of AKI

14.1.2. Market Size by Therapies

15. EU-5 Countries: Market Outlook

15.1. Germany Market Size

15.1.1. Total Market size of AKI

15.1.2. Market Size by Therapies

15.2. France Market Size

15.2.1. Total Market size of AKI

15.2.2. Market Size by Therapies

15.3. Italy Market Size

15.3.1. Total Market size of AKI

15.3.2. Market Size by Therapies

15.4. Spain Market Size

15.4.1. Total Market size of AKI

15.4.2. Market Size by Therapies

15.5. United Kingdom Market Size

15.5.1. Total Market size of AKI

15.5.2. Market Size by Therapies

16. Japan: Market Outlook

16.1. Japan Market Size

16.1.1. Total Market size of AKI

16.1.2. Market Size by Therapies

17. Trends in the Cost of Therapies in Acute Kidney Injury

18. Market Access and Reimbursement Scenario of Acute Kidney Injury

18.1. Centers of Medicare and Medicaid Services (US)

18.2. American Kidney Fund (AKF)

18.3. Reimbursement and Cost of Acute Kidney Injury in Europe

18.3.1. United Kingdom (England)

18.3.2. France

18.3.3. Germany

18.3.4. Italy

19. Market Drivers

20. Market Barriers

21. Case Reports

21.1. A simple real-time model for predicting acute kidney injury in hospitalized patients in the US: A descriptive modeling study

21.2. Acute kidney injury in the UK: a replication cohort study of the variation across three regional populations

21.3. Exercise-Induced Acute Kidney Injury in a Police Officer with Hereditary Renal Hypouricemia (Japan)

22. SWOT Analysis for Acute Kidney Injury

23. Appendix

23.1. Report Methodology

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Related Articles